Survey finds 86% of patients with psychosis willing to try CBD as treatment
Among 70 patients with psychotic disorders, 86% were willing to try CBD as a treatment, 69% believed it would improve their symptoms, and 64% expected fewer side effects than current antipsychotic medications.
Quick Facts
What This Study Found
86% of patients were willing to try CBD. 69% believed CBD would improve their psychotic symptoms. 64% expected CBD to have fewer side effects than their current medications (mainly antipsychotics). Only 10% were concerned CBD might worsen psychosis, and this appeared to reflect confusion between CBD and cannabis.
Key Numbers
70 patients surveyed; 86% willing to try CBD; 69% expected symptom improvement; 64% expected fewer side effects; 10% concerned about worsening psychosis.
How They Did This
Survey of 70 patients with psychotic disorders assessing expectations about CBD efficacy and side effects.
Why This Research Matters
Patient acceptability is crucial for treatment success, especially in psychosis where medication adherence is a major challenge. The high willingness to try CBD, combined with its emerging evidence and low side effect profile, makes it a promising candidate.
The Bigger Picture
The high acceptability of CBD among psychosis patients reflects broader public awareness of cannabis-derived compounds. If clinical trials confirm efficacy, CBD could improve adherence rates that plague antipsychotic treatment.
What This Study Doesn't Tell Us
Small sample (n=70). Patients may conflate expectations with hopes. Acceptability does not predict efficacy. No assessment of patient understanding of the difference between CBD and THC. Selection bias toward patients open to novel treatments.
Questions This Raises
- ?Would the 10% who feared worsening change their minds with proper education about CBD vs. THC?
- ?Does high acceptability translate to better adherence if CBD is prescribed?
- ?What dose would be needed for antipsychotic effects?
Trust & Context
- Key Stat:
- 86% of psychosis patients willing to try CBD treatment
- Evidence Grade:
- Small cross-sectional survey assessing acceptability, not efficacy.
- Study Age:
- Published in 2022.
- Original Title:
- Acceptability of cannabidiol in patients with psychosis.
- Published In:
- Therapeutic advances in psychopharmacology, 12, 20451253221128445 (2022)
- Authors:
- Chesney, Edward(13), Lamper, Doga, Lloyd, Millie(2), Oliver, Dominic, Hird, Emily, McGuire, Philip
- Database ID:
- RTHC-03756
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Would patients with psychosis accept CBD treatment?
Yes, based on this survey. 86% of patients were willing to try CBD, driven by expectations of symptom improvement and fewer side effects than their current antipsychotic medications.
Were patients concerned CBD might worsen psychosis?
Only 10% expressed this concern, and the researchers noted this appeared to stem from confusion between CBD (which has potential antipsychotic properties) and cannabis (which contains THC that can worsen psychosis).
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03756APA
Chesney, Edward; Lamper, Doga; Lloyd, Millie; Oliver, Dominic; Hird, Emily; McGuire, Philip. (2022). Acceptability of cannabidiol in patients with psychosis.. Therapeutic advances in psychopharmacology, 12, 20451253221128445. https://doi.org/10.1177/20451253221128445
MLA
Chesney, Edward, et al. "Acceptability of cannabidiol in patients with psychosis.." Therapeutic advances in psychopharmacology, 2022. https://doi.org/10.1177/20451253221128445
RethinkTHC
RethinkTHC Research Database. "Acceptability of cannabidiol in patients with psychosis." RTHC-03756. Retrieved from https://rethinkthc.com/research/chesney-2022-acceptability-of-cannabidiol-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.